Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President and CEO

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-03	Premium	acquired	Premium	Premium	Premium	-
2024-01-03	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-12-22	Premium	gifted	Premium	Premium	Premium	-
2023-12-12	Premium	gifted	Premium	Premium	Premium	-
2022-07-27	Premium	bought	Premium	Premium	Premium	-
2022-07-27	Premium	bought	Premium	Premium	Premium	President and CEO
2022-07-27	Premium	bought	Premium	Premium	Premium	-
2021-12-02	Premium	gifted	Premium	Premium	Premium	-
2021-11-23	Premium	bought	Premium	Premium	Premium	-
2021-11-19	Premium	bought	Premium	Premium	Premium	-
2021-11-19	Premium	bought	Premium	Premium	Premium	President and CEO
2021-06-29	Premium	bought	Premium	Premium	Premium	-

ACXP - Acurx Pharmaceuticals, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for ACXP